Company intelligence / Profile preview
Phebra
Sydney, New South Wales, Australiaphebra.com ↗
- Ownership
- Private
- Employees
- ~120
- Development stage
- Other
01
Overview
Phebra manufactures and supplies over 65 critical medicines for hospital specialty use. It has a strong presence in Australia and export markets. The company is involved in licensing agreements with partners such as Medsenic for the oral formulation of arsenic trioxide targeting several autoimmune and inflammatory conditions. Its Lane Cove West facility is GMP-compliant and licensed by the Australian TGA.
- Therapeutic areas
- ImmunologyRheumatologyInfectious DiseasesNeurology
- Modalities
- Small moleculeBiologic
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Medsenic/BioSenic Group – licensing agreement for oral arsenic trioxide ("OATO")
Beyond the preview
Go deeper on Phebra.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Phebra.